Noninferiority of Ultra-thin Biodegradable Polymer Sirolimus Eluting Stents in Diabetic PatientsNew stent type shows promise for patients with diabetes and heart disease

This multicenter randomized controlled trial evaluated the clinical performance of the Supraflex Cruz sirolimus-eluting stent (SES) against the Xience everolimus-eluting stent (EES). The study specifically targeted a high-risk patient population: those diagnosed with diabetes mellitus and multivessel coronary artery disease undergoing percutaneous coronary intervention. With a substantial sample size of 1,800 patients, the trial aimed to establish whether an ultra-thin biodegradable polymer platform could match the efficacy of established durable polymer technologies in complex coronary environments.

The primary endpoint was defined as target lesion failure (TLF) at one year follow-up. TLF is a composite metric including cardiac death, target vessel myocardial infarction, and ischemia-driven target lesion revascularization. This rigorous endpoint allows clinicians to assess the overall success of the intervention in preventing major adverse cardiac events within the treated segment.

Results indicated that the primary endpoint was met with statistical significance. The incidence of TLF was 7.92% for patients receiving the sirolimus-eluting stent compared to 8.75% for those receiving the everolimus-eluting stent. The one-sided upper 97.5% confidence bound was 3.42%, yielding a p-value of 0.005, thereby confirming noninferiority. This suggests that the thinner polymer architecture does not compromise patient outcomes in this specific demographic.

Secondary outcomes further supported these findings. Cardiac death rates were comparable between groups (3.6% vs. 3.4%). Target vessel myocardial infarction was observed at 6.61% and 7.54%, respectively, showing no statistically significant difference. Similarly, ischemia-driven target lesion revascularization remained low and balanced across both cohorts (0.8% vs. 1.0%), indicating stable performance for both stent types.

Safety profiles regarding stent thrombosis were also comparable, with rates of 1.0% and 0.7%, respectively. Nonfatal myocardial infarction rates were 4.7% in the sirolimus group versus 6.4% in the everolimus group, again showing no significant clinical divergence between the two technologies. These results suggest that the choice of polymer platform—biodegradable vs. durable—does not significantly impact early-term safety markers.

For clinicians managing patients with diabetes and complex multivessel disease, these findings provide evidence for the use of ultra-thin biodegradable polymer stents. The data suggests that such devices offer a reliable alternative to established durable polymers. By meeting noninferiority criteria, the sirolimus-eluting stent provides a viable option for maintaining high standards of care in patients with compromised microvasculature due to diabetes.